Free tool
FAERS Monitor: Taxotere
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020449 or its brand name (Taxotere, Docetaxel). Reports on generic versions are filed under their own applications.
Reports
68,067
Serious
53,536
79% of reports
Hospitalization
20,856
Death reported
8,967
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- alopecia16,994
- madarosis6,718
- hair texture abnormal5,993
- hair colour changes5,874
- hair disorder5,625
- diarrhoea5,333
- nausea3,877
- emotional distress3,615
- anxiety3,462
- neutropenia3,415
- fatigue3,285
- febrile neutropenia3,101
- vomiting2,825
- malignant neoplasm progression2,800
- disease progression2,702
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 311 |
| 2005 | 420 |
| 2006 | 369 |
| 2007 | 442 |
| 2008 | 633 |
| 2009 | 879 |
| 2010 | 947 |
| 2011 | 1,384 |
| 2012 | 1,780 |
| 2013 | 1,648 |
| 2014 | 1,567 |
| 2015 | 2,012 |
| 2016 | 2,281 |
| 2017 | 4,814 |
| 2018 | 10,853 |
| 2019 | 7,728 |
| 2020 | 5,638 |
| 2021 | 4,532 |
| 2022 | 4,137 |
| 2023 | 4,129 |
| 2024 | 4,611 |
| 2025 | 4,120 |
| 2026 | 2,832 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,986,092 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hair disorderSignal | 5,625 | 661.2 | 631.6 | 1,179,422 |
| madarosisSignal | 6,718 | 422.6 | 407.7 | 1,192,404 |
| hair colour changesSignal | 5,874 | 275.1 | 265.8 | 848,143 |
| hair texture abnormalSignal | 5,993 | 249.8 | 241.6 | 820,771 |
| alopeciaSignal | 16,994 | 29.2 | 28.8 | 426,379 |
| febrile neutropeniaSignal | 3,101 | 15.1 | 14.6 | 39,043 |
| emotional distressSignal | 3,615 | 9.5 | 9.2 | 26,748 |
| malignant neoplasm progressionSignal | 2,800 | 8.7 | 8.3 | 18,530 |
| neutropeniaSignal | 3,415 | 7.9 | 7.7 | 20,304 |
| disease progressionSignal | 2,702 | 7.2 | 6.9 | 14,164 |
| anxietySignal | 3,462 | 3.8 | 3.7 | 7,127 |
| diarrhoeaSignal | 5,333 | 2.6 | 2.5 | 5,212 |
| vomiting | 2,825 | 1.9 | 1.8 | 1,145 |
| nausea | 3,877 | 1.5 | 1.5 | 704 |
| fatigue | 3,285 | 1.3 | 1.3 | 242 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.